Country Information


Botswana

 
HIV prevalence 15-49, 2007/2008 23.9%
Tuberculosis death rate 95/100,000 population
Malaria death rate (children under 5) 72/100,000 population
 
   
             
     
  Botswana is a land-locked nation in south central Africa, located on South Africa's northern border. Botswana is about the size of Texas but has a population of only 1.6 million. The small population is a result of Botswana's aridity; two-thirds of the nation is taken up by the Kalahari Desert, and only 5 percent of Botswana's land is arable.

The presence of diamonds and other mineral resources has made Botswana wealthy relative to other African nations. The per capita GNI of more than $3,000 is deceptive, however, as wealth is unevenly distributed, and a quarter of the working age population is unemployed.

Botswana has been devastated by HIV/AIDS. Almost 39 percent of the adult population is HIV-positive. Reversing the trend of rapid population growth seen in most African nations, AIDS is expected to result in Botswana's population falling by a quarter by 2025. (Botswana's President Festus Mogai reported in a November 2003 speech that the incidence rate appears to have fallen to 35.4% in 2002, but much of the decrease is due to deaths.) Botswana's HIV prevalence rate is the second highest in the world, superceded only by that of Swaziland.

TB prevalence in Botswana is currently 231 per 100,000, with a death rate of about 43 per 100,000. One of the goals of the BOTUSA Project, a joint venture of the Botswana Ministry of health and the CDC, is to address the growing problem of TB in Botswana.

Malaria is endemic in the northern parts of Botswana, including Kasane and Francistown, but generally not in the south. WHO reports that in 2000 the malaria death rate for children ages 0-4 was 72 per 100,000.

Sources: Synergy, CDC, United Nations Statistical Division

 
           
             
  According to a November 2003 Human Sciences Research Council report, Botswana spends approximately 10.4% of its government revenues on the health sector. This is below the 15% of resources pledged at the 2001 Abuja conference. In per capita dollar terms, Botswana is spending around $191 per capita per year in the health sector.

Botswana established a National AIDS Council in 1989. A National AIDS Co-ordinating Agency (NACA) was set up in 2000 and was given responsibility for mobilising and co-ordinating a multi-sectorial national response to HIV and AIDS. This organization is chaired by the President and is also the secretariat for the National AIDS Council.

Botswana has concluded its National Multisectoral Second Medium Term Plan for HIV/AIDS (MTP2: 1997-2002). The triad of objectives included in this strategic plan were:

  • Preventing sexual transmission of HIV.
  • Ensuring the safety of the blood supply.
  • Caring for people living with HIV/AIDS (PLWHA) and their families.

Awareness campaigns targeted to high-risk populations and the social marketing of condoms were activities undertaken to achieve the first objective. Since the beginning of 2004, HIV tests are given as a routine part of checkups in both public and private clinics in Botswana. The testing is compulsory but routine, however patients can opt out. This makes Botswana the first country in Africa to have a national policy of routinely offering HIV test, on a voluntary basis.

An estimated 110,000 Botswana are in need of ARV treatment, and approximately 17,500 were receiving treatment in the first quarter of 2004. Botswana hopes to double that by the end of 2005.

The government of Botswana has also established a pilot project for preventing mother-to-child-transmission (MTCT) of HIV by treating HIV-positive pregnant women with AZT. The MTCT program is implemented in collaboration with UNICEF, and the government has committed $3.6 million per year to support it. Many women who receive MTCT counseling have refused to be tested for HIV.

The need for doctors, pharmacists, and health care technicians to treat HIV/AIDS is rising, and Botswana has no medical school. Even though government has anti-AIDS programs in place, but it has a hard time keeping people on staff and loses many of its skilled health care professionals to corporations and partners including NGOs, all of whom pay better than the government, says President Mogai. Currently, Botswana is building a medical school and trying to train more of its own people.

A National Strategic Plan on HIV/AIDS (2003–2009) has been developed to achieve an expanded multisectoral response at to expand upon previous advances.

In its efforts against TB and malaria, Botswana has adopted a DOTS program, and about 71 percent of TB cases are treated under DOTS protocols. In 2000 the government of Botswana undertook a major campaign to eliminate mosquitoes as a measure to control malaria.

Sources: HSRC report, Synergy, UNICEF, Congressional Black Caucus Foundation (October 30, 2003), United Nations Statistics Division, AllAfrica.com: IRIN, March 11 2004, interview with Dr. Ndwapi Ndwapi, VOA news; UNAIDS; www.avert.org

 
           
             
 
Total population. mid-2009 2.0 (millions)
HIV prevalence 15-49, 2007/2008 23.9%
Tuberculosis death rate 95/100,000 population
Prevalence of tuberculosis per 100,000 population, 2000 490
Prevalence of tuberculosis per 100,000 population, 2004 553
% Tuberculosis detection rate under DOTS, 2001 69
% Tuberculosis detection rate under DOTS, 2004 67
% Tuberculosis treatment success rate under DOTS, 2000 77
% Tuberculosis treatment success rate under DOTS, 2003 77
Malaria death rate (children under 5) 72/100,000 population
GNI PPP Per Capita, 2008 13,100 (US$)
Life expectancy at birth 49 years
Infant mortality rate 48/1,000 live births
Total fertility rate 3.2 per woman
Crude birth rate 25/1,000 population
Crude death rate 12/1,000 population
Adult male literacy level 86% (pct. 15+ literate)
Adult female literacy level 93% (pct. 15+ literate)
Contraceptive prevalence rate, modern methods 42% of women in union
Estimated number of people living with HIV: Adults and Children, 2005 270,000
Estimated number of people living with HIV: Adults and children, end 2003 350,000
Estimated number of people living with HIV: Adults and children, end 2001 350,000
Estimated number of people living with HIV: Adults (15+), 2005 260,000
Estimated number of people living with HIV: Adults (15-49), end 2003 330,000
Estimated number of people living with HIV: Adults (15-49), end 2001 330,000
Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 37.3%
Estimated number of people living with HIV: Adults (15-49) rate (%), 2003 38.0%
Estimated number of people living with HIV: Women (15+), 2005 140,000
Estimated number of people living with HIV: Women 15-49, end 2003 190,000
Estimated number of people living with HIV: Women 15-49, end 2001 190,000
Estimated number of people living with HIV: Children (0-14), 2005 14,000
Estimated number of people living with HIV: Children (0-14), end 2003 25,000
Estimated number of people living with HIV: Children (0-14), end 2001 22,000
Estimated number of AIDS deaths: Adults and children, 2005 18,000
AIDS deaths in adults and children, end 2003 33,000
AIDS deaths in adults and children, end 2001 28,000
Estimated number of orphans due to AIDS: Children (0-17), 2005 120,000
Orphans due to AIDS (0-17), living 2003 120,000
Orphans due to AIDS (0-17), living 2001 95,000

Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.

 
           
             
  Botswana’s public health system consists of 23 district health teams, 3 referral hospitals, 12 district hospitals, 17 primary hospitals, 222 clinics, 330 health posts and 740 mobile stops. The 237 bed Princess Marina Hospital in Gaborone is the largest private health care institution in the country. President Mogae reported in a November 2003 speech that 60% of acute care hospital beds in Botswana are occupied by AIDS patients.

The WHO estimates that Botswana had 23.8 physicians and 219.1 nurses per 100,000 population in 1994. In a November 2003 speech President Mogae spoke very frankly about the need to recruit health professionals away from other African countries.

Sources: Botswana Government Website, WHO

 
           
             
 

Although the University of Botswana has a faculty of science, Botswana's lack of a national medical school is a considerable impediment to pursuing research in the country, as well as a primary reason behind Botswana's chronic deficiency in trained medical personnel.

 
           
             
 

There are currently many initiatives aimed a combatting HIV/AIDS in Botswana. One of the most publicized of these initiatives is the African Comprehensive HIV/AIDS Partnerships (ACHAP). This partnership is a collaboration between Botswana's government, the Bill & Melinda Gates Foundation and the Merck Company Foundation. ACHAP was established in July 2000 to supporting the goals of the Botswana Government in decreasing HIV incidence and significantly increasing the rate of diagnosis and treatment of the disease.

Source: www.avert.org

Entity

Project Title

Diseases

Primary Category

Secondary Category

NIH HIV Vaccine Clinical Trial Unit HIV/AIDS Drug Development  
  (Principal Investigator: Raphael Dolin. 2000-2005.) This HIV Vaccine Clinical Trial Unit (HVTU) is a part of the HIV Vaccine Trials Network (HVTN),...

NIH Cost-Effectiveness of HAART for HIV and AIDS in Botswana HIV/AIDS Drug Development  
  (PI: Richard Marlink. 2003-2006.) An economic analysis to determine the average costs per person for implementing HAART, incremental...

NIH Respiratory Diseases/BSI Study HIV/AIDS Drug Development  
  (PI: Shahin Lockman. 2000-2005.) The primary study objectives are to determine the efficacy and safety of zidovudine (ZDV) given for 6 months to...

NIH Prevention of Milk-borne Transmission of HIV in Botswana HIV/AIDS Drug Development  
  (PI: Myron Essex. 2000-2005.) This study will investigate the outcomes of HIV-positive mothers breastfeeding their infants in conjunction with...

NIH Diarrheal Disease Study HIV/AIDS Drug Development  
  (PI: Roger Shapiro. 2000-2005.) This is a study of diarrheal disease among infants in the Harvard AIDS Institute and the AIDS/STD Unit of Botswana...

NIH HIV Disease, Drug Abuse & Nutrient Therapy in Botswana HIV/AIDS Drug Development  
  (PI: Marianna Baum. 2003-2008.) This study involves using a randomized factorial design with 828 HIV+ volunteers to investigate the efficacy of...

NIH A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants HIV/AIDS Drug Development  
  (Study Chairs: Donald S. Burke, Salim Abdool Karim. 2004-2006). This study will assign 96 participants in the United States, South Africa, and...

NIH Alcohol Use and the Risk of HIV-1 Infection in Botswana HIV/AIDS Epidemiology Prevention
  (PI: George Seage. 2003-2006.) The focus of this study is on the role of alcohol in condom use and unsafe sex practices in Botswana.

NIH Early and Acute HIV-1 Subtype C Infection in Botswana HIV/AIDS Epidemiology Drug Development
  (PI: Vladimir Novitsky. 2003-2005.) The purpose of this study is to better understand how HIV interacts with the human immune system in the early...

NIH Molecular Analysis of HIV-1C Transmission Cofactors HIV/AIDS Epidemiology  
  (PI: Monty Montano. 2003-2006) In this study, the investigators propose to evaluate molecular correlates of HIV-1 entry and replication in order to...

NIH Identification of HLA Restricted CTL Epitopes of HIV-1 C HIV/AIDS Epidemiology  
  (PI: Myron Essex. 2000-2005.) The study will determine the frequency of the most common HLA types in Botswana, conduct a molecular characterization...

NIH Genomic Analysis of HIV-1 Transmission in Botswana HIV/AIDS Epidemiology  
  (PI: Myron Essex. 1999-2004.) No further information about this grant is available.

NIH Exploring Attitudes Toward AIDS Prevention in Botswana HIV/AIDS Epidemiology Prevention
  (PI: Marie Brown. 2002-2005) A social sciences study of HIV/AIDS-related knowledge and attitudes among college students in Botswana.

NIH Health of HIV-Infected Mothers After pMTCT, Botswana HIV/AIDS Prevention Epidemiology
  (PI: Shahin Lockman. 2003-2008.) To this point there has been little research on health outcomes for HIV+ mothers who are involved in prevention of...

NIH AIDS and TB Research Training Program for Botswana HIV/AIDS,Tuberculosis Capacity  
  (PI: Sheila Tlou. 2002-2003.) A capacity building collaboration between Harvard and Botswana responding to the fact that TB is now responsible for...

Other US Phase III Trial of HSV-2 Suppression in Sero-Discordant Couples and Substudy on Role of TNF-a in HIV-1 Transmission HIV/AIDS Drug Development Prevention
  (Study Chair: Connie Celum)The purpose of this trial is to determine whether the treatment of HSV-2 infection in an HIV-infected participant will...

Other US The Adult Antiretroviral Treatment and Resistance Study (Tshepo) HIV/AIDS Drug Development  
  (PI: Richard Marlink) This study is designed to compare antiretroviral treatments and drug resistant strains of HIV. Six different treatment...

Other US Botswana TDF/FTC Oral HIV Prophylaxis Trial HIV/AIDS Drug Development Prevention
  Centers for Disease Control and Prevention, Botwana Ministry of Health, Gilead Sciences (PIs: Lynn Paxton, Poloko Kebaabetswe). This trial is...

Other US Botswana Study of UC-781 Vaginal Microbicide HIV/AIDS Drug Development Prevention
  Centers for Disease Control and Prevention, CONRAD (Study Directors: Lisa Grohskopf, Christine Mauck; PI: Dawn Smith). This Phase I trial is...

Other US Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-Infected Persons in Botswana Tuberculosis Drug Development  
  Centers for Disease Control and Prevention (PI: Taraz Samandari). This trial is designed to compare the benefits of continued versus limited...

Other US Botswana Diarrheal Diseases Study HIV/AIDS Epidemiology  
  Harvard School of Public Health and Botswana Ministry of Health (PI: Roger Shapiro). Breast-fed babies born to HIV-infected mothers will be...

Other US Botswana Tenofovir Oral HIV Prophylaxis Trial HIV/AIDS Prevention  
  Centers for Disease Control and Prevention, Botswana Ministry of Health, Gilead Sciences (Study Chairs: Dawn Smith, Lynn Paxton). This study has...

Other US Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana HIV/AIDS Capacity General
  University of Pennsylvania (Study Directors: Darren Linkin, James Thompson, Andrew Steenhoff; PI: Harvey Friedman). The investigators will...

Other US Botswana Pediatric Respiratory Disease and Bloodstream Infection Study HIV/AIDS General  
  Harvard School of Public Health (PI: Shahin Lockman). Infants born to HIV-infected mothers will be monitored for lower respiratory tract and...

Other US CDC: The BOTUSA Project HIV/AIDS,Tuberculosis General  
  The BOTUSA Project is part of the collaboration between the Global AIDS Program (GAP) of the CDC in the United States, and Botswana's Ministry of...

Other US USAID HIV/AIDS,Tuberculosis General  
  Botswana graduated from USAID development assistance in 1996. During the last year it received development assistance, USAID provided...

International A Study to Examine the Human Papillomavirus Types Exposure in Women from Southern Africa and Brasil HIV/AIDS Drug Development  
  University of Witwatersrand, South Africa, and Merck (PI: Cynthia S. Firnhaber). This study will be conducted in Botswana, South Africa, and...

International A Phase 1 Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children HIV/AIDS Drug Development  
  Boehringer Ingelheim Pharmaceuticals. This trial will be conducted in Botswana, Germany, Romania, and the United States. Enrolling children...

International Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety, and Acceptability HIV/AIDS Prevention  
  Brigham and Women's Hospital (PI: Rebecca M. Plank). Approximately a thousand newborn male infants will be enrolled in this clinical trial of...

International Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) HIV/AIDS General  
  In December 2003 Botswana signed a grant agreement with the Global Fund for an $18.6 million HIV/AIDS program that will focus on recruiting and...

International European Union HIV/AIDS General  
  Over the past years, the EU has funded the National STD Referral, Research and Training Center and has helped set up the Women and AIDS Project. It...

NGO GlaxoSmithKline ITN Study Malaria Prevention  
  Study to Evaluate Community Perspective on the Use of Impregnated Linen for Malaria Control in Botswana. (Principal Investigators: R. Diseko, D.W....

NGO Merck HIV/AIDS General  
  The pharmaceutical giant Merck has pledged $50 million over five years for the 'Masa' (New Dawn) anti-HIV/AIDS program in Botswana. Masa provides...

NGO Bristol Myers Squibb: Secure the Future Programs HIV/AIDS General  
  Botswana was included in Bristol-Myers Squibb's five-nation $100 million Secure the Future anti-HIV/AIDS campaign launched in 2000. Other nations...

Foundation Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults with Cryptococcal Meningitis HIV/AIDS Drug Development General
  Botswana-UPenn Partnership, Doris Duke Charitable Foundation, University of Pennsylvania (PIs: Gregory P Bisson, Pablo Tebas). The investigators...

Foundation Adult Antiretroviral Treatment and Resistance Study (Tshepo) HIV/AIDS Drug Development General
  (Bristol-Myers Squibb Secure the Future Foundation. PI: Richard Marlink. 1999-2007). In this trial, HIV-infected participants are assigned to one...

Foundation Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission HIV/AIDS Drug Development Prevention
  (Study Chairs: Connie Celum, Jairam Lingappa, Anna Wald. Botswana PIs: Ibou Thior, Max Essex) This study will enroll 3000 couples in Africa in...

Foundation Gates Foundation HIV/AIDS,Tuberculosis General  
  The Bill and Melinda Gates Foundation is supporting various HIV/AIDS programs in Africa including a five-year initiative to expand national...

 
           
             
 
  1. Future goals of the BOTUSA Project (the local CDC Global AIDS Program) include:
    • Strengthening HIV/AIDS education in the schools
    • Increasing the coverage of Voluntary Counseling and Testing (VCT) programs
    • Reducing Mother-to-Child transmission
    • Increasing the availability of TB preventive treatments using isoniazid as a prophylactic, and anti-retroviral treatments for AIDS patients
    • Improving
    ... additional information

 
           



Home || HIV/AIDS || Tuberculosis || Malaria || Advanced Search || Links || Contact Us

Last site update: November 17, 2009

For questions, or to report problems with this site, please contact the Webmaster.

Disclaimer